1,500 packages of Areplivir were received for the treatment of doctors in the Leningrad region

This year, the Leningrad Region became the last region whose doctors received 1,500 packages of coronavirus medicine free of charge as part of the PROMOMED Group's charity program Areplivir – Doctors. In total, since the launch of the All-Russian campaign in October 2020, over 11 thousand packages of the most effective and safe COVID-19 drug have been transferred for the treatment of medical workers in Moscow, Samara, Saratov, Sverdlovsk regions, the Republic of Mordovia, Perm Krai and other regions of Russia.

The program was launched in the Leningrad Region on December 25 during the visit of the PROMOMED Group of Companies delegation. During the meeting of the company's management with Deputy Prime Minister Nikolai Yemelyanov and Chairman of the Health Committee Sergey Vylegzhanin, it was noted that to date, over 22.4 thousand cases of COVID-19 infection have been recorded in the region, a significant part of which are among doctors of medical institutions specializing in the treatment of coronavirus infection.

According to Nikolai Yemelyanov, medical care for hospitals in the Leningrad region is needed today more than ever. "Thank you for helping to keep our doctors safe during this difficult time, who are at the forefront of the fight against coronavirus. Together with socially responsible business, we will be able to defeat the epidemic faster and preserve the health of hundreds of doctors and thousands of patients," he said. "I am confident that our meeting will mark the beginning for further cooperation." In turn, the head of the Regional Health Committee, Sergey Vylegzhanin, noted that the spread of the disease is causing increased concern, therefore, in the current situation, any support is met with gratitude.

"We are sending a certain amount of Areplivir specifically to doctors working in the "red zone", to medical personnel who directly treat patients with COVID-19. We believe that even one saved doctor's life saves the lives of a much larger number of patients," explained Andrey Mladentsev, Chief Executive Officer of Promomed, the purpose of the program. And Dmitry Pushkar, one of the heads of clinical trials of Areplivir, Academician of the Russian Academy of Sciences, Honored Doctor of the Russian Federation, stressed that starting therapy with the drug at an early stage of the disease allows patients with coronavirus infection to be transferred to the outpatient category. "We not only protect patients from the severe course of the disease, but also seriously reduce the burden on the entire healthcare system," said the professor.

 At the end of the working meeting, Kira Zaslavskaya, head of the PROMOMED Medical Department, invited the chief physicians of the Leningrad region to exchange views on the clinical use of the drug and confirmed the company's willingness to share existing experience.

PROMOMED Group is a leader in the domestic pharmaceutical industry in the production of anti-infection drugs with its own scientific and production site of JSC Biochemist in Saransk. The company's portfolio includes more than 150 names of medicines, 80% of which are included in the list of VED.

Areplivir (INN: Favipiravir) is the latest direct antiviral drug for the treatment of coronavirus infection, included in the guidelines of the Russian Ministry of Health for the treatment of COVID-19. By order of the Government of the Russian Federation, it is included in the list of vital and essential medicines. The selling price fixed by the Federal Antimonopoly Service has made Areplivir one of the most affordable medicines against the SARS-CoV-2 coronavirus.